Professor Jeanne Tie

Professor Jeanne Tie



Professor Jeanne Tie at her desk



MBChB Otago MD Melbourne FRACP

Clinical Research Fellow

I am a medical oncologist with a special interest in colorectal cancer.

My research is aimed at understanding the features of colorectal cancer that predict how a patient will experience the disease, such as whether they will respond to therapy and whether they are at risk of recurrence following surgery.

I am also exploring whether a simple blood test could be used for the early detection of cancer, diagnosing tumours before they spread, when the chance of cure is high. 

Research interest 

My research focuses on understanding the clinical utility of circulating tumour DNA (ctDNA), particularly in early stage disease. 

ctDNA is shed by tumour cells into the blood and can be used as a type of ‘liquid biopsy’, revealing features of the tumour that may predict disease course or response to therapy. Our group recently found that ctDNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.   

I am now performing prospective, randomised studies in stage II colon and stage III colon cancer, where patients are randomised to ctDNA informed treatment or to standard of care. For those in the ctDNA informed treatment group, we use ctDNA analysis to define recurrence risk and guide adjuvant therapy decision making. 

I am also part of an international collaboration developing a blood test for the early detection of eight common cancers. 

Two female researchers outside a laboratory

Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.

Two researchers smiling at the camera

An international research team has developed a new blood test for the early detection of eight common cancers, diagnosing tumours before they have spread, when the chance of cure is high.

Associate Professor Jeanne Tie at a lab bench

Dr Jeanne Tie and colleagues have designed a blood test to determine the risk of colon cancer recurrence after surgery.